Medical Doctor Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Tony Asante

Pain Medicine Cape Girardeau, MO Medical Doctor

NPI 1083078752 CMS profile 2785702

211 Saint Francis Dr, Cape Girardeau, MO 63703

Open in the dashboard

General payments

$4,995

111 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Tony Asante of Cape Girardeau, MO is reported in the CMS Open Payments database as having received $4,995 across 111 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 66th percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,725 36
2024 General $2,106 41
2023 General $389 15
2022 General $464 14
2021 General $311 5

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Tony Asante
  • Pain Medicine median
  • Middle half of Pain Medicine
  • National median

In program year 2025, general payments to Tony Asante were reported at $1,725. Among 2,779 Pain Medicine profiles paid that year, the median was $458 and the middle half received between $124 and $1,401.

Show as a table
Year Tony Asante Pain Medicine median Middle half National median
2019 $0 $498 $126–$1,682 $163
2020 $0 $284 $80–$910 $114
2021 $311 $399 $112–$1,219 $132
2022 $464 $455 $137–$1,484 $149
2023 $389 $484 $128–$1,495 $160
2024 $2,106 $498 $131–$1,540 $164
2025 $1,725 $458 $124–$1,401 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Boston Scientific Corporation $2,953 47 payments
  2. Medtronic, Inc. $1,517 50 payments
  3. Stryker Corporation $160 1 payment
  4. Foundation Fusion Solutions, LLC $119 3 payments
  5. Nevro Corp. $95 2 payments
  6. Collegium Pharmaceutical, Inc. $63 4 payments
  7. BIOTRONIK NRO, Inc. $31 1 payment
  8. Saluda Medical Americas, Inc. $30 1 payment
  9. Vertex Pharmaceuticals Incorporated $14 1 payment
  10. Amgen Inc. $13 1 payment

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $2,660 102 payments
  2. Travel and Lodging $2,335 9 payments
Products named General payments · program years 2021–2025
  1. WaveWriter Alpha Prime 16 $1,405 39 payments
  2. INTELLIS ADAPTIVESTIM $1,035 36 payments
  3. INTELLIS $311 5 payments
  4. MILD DEVICE KIT $160 1 payment
  5. OMNICURVE $160 1 payment
  6. INCEPTIV $123 7 payments
  7. Intracept Intracept Access Instruments (Gen 3)_NMOD $114 1 payment
  8. Senza $95 2 payments
  9. Intracept Contains (1)Intracept RF Probe (2)Intracept Access Instruments_NMOD $35 1 payment
  10. XTAMPZA $32 2 payments
  11. Other $192 10 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

455

Median for Pain Management: 951

Drug cost

$5,799

Median for Pain Management: $26,034

Branded share of claims

14.3%

Median for Pain Management: 29.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 44 $1,695
Tramadol Hcl Generic 217 $1,434
Pregabalin Generic 44 $1,092
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 21 $536
Gabapentin Generic 44 $481
Diclofenac Sodium Generic 21 $223
Tizanidine Hcl Generic 30 $221
Cyclobenzaprine Hcl Generic 12 $59
Meloxicam Generic 22 $56

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,732 Part D prescribers listed as Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 28 billing codes

Paid by Medicare

$67,080

Medicare's payments for the services billed

Medicare patients

451

Average age 72

Services billed

1,040

270 women, 181 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 34%
Ischemic heart disease 28%
Depression 28%
COPD 25%
Chronic kidney disease 22%
Osteoporosis 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

111 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pain Medicine in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record